<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01257061</url>
  </required_header>
  <id_info>
    <org_study_id>DECEMS1010</org_study_id>
    <nct_id>NCT01257061</nct_id>
  </id_info>
  <brief_title>Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema Treatment</brief_title>
  <official_title>Unicentric Comparing Effectiveness Superiority of to Clemastine Fumarate 1, 0 mg/g + Dexamethasone 0, 5 mg/g to Dexchlorpheniramine Maleate 10 mg/g in Eczema Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atopic dermatitis is a recurrent pruritic skin disorder which has a significant morbidity and
      impaired quality of life due specially pruritus and physical visible skin lesions. The
      propose of this trial is evaluate the effectiveness of clemastine fumarate 1, 0 mg/g +
      dexamethasone 0, 5 mg/g compared to dexchlorpheniramine maleate 10 mg/g in eczema treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design:

      • Double blinded, superiority, prospective parallel-group, intend to treat trial.

      Study design:

        -  Experiment duration: 22 days

        -  2 visits (days 1,7,15 and 22)

        -  Reducing Eczema Area and severity index evaluation

        -  Adverse events evaluation
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction / improvement of signs and symptoms</measure>
    <time_frame>DAY 22</time_frame>
    <description>The reduction of signs an symptoms will be evaluated by OSAAD index.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events Evaluation</measure>
    <time_frame>DAY 22</time_frame>
    <description>Adverse events will be collected and followed in order to evaluate safety and tolerability.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Eczema</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexchlorpheniramine maleate 10 mg/g</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 1</intervention_name>
    <description>Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g applied 2 times / day at lesion</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 2</intervention_name>
    <description>Dexchlorpheniramine maleate 10 mg/g applied 2 times / day at lesion</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must be able to understand the study procedures agree to participate and give
             written consent.

          2. Patients with acute or sub-acute eczema.

          3. Presence of symmetric lesions to compare on side to the other.

        Exclusion Criteria:

          1. Pregnancy or risk of pregnancy.

          2. Lactation

          3. Use of anti-inflammatory or immunosuppressive drugs (last 30 days prior to the study).

          4. Sunlight over exposure in the last 15 days.

          5. Any pathology or past medical condition that can interfere with this protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Flavia Addor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medcin Instituto da Pele</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felipe Pinho, MD</last_name>
    <role>Study Director</role>
    <affiliation>EMS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Flavia Addor</last_name>
    <phone>5511 3681 6362</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Medcin instituto da Pele</name>
      <address>
        <city>Osasco</city>
        <state>São Paulo</state>
        <zip>060323-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flavia Addor</last_name>
      <phone>5511 3681 6362</phone>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2010</study_first_submitted>
  <study_first_submitted_qc>December 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2010</study_first_posted>
  <last_update_submitted>March 1, 2013</last_update_submitted>
  <last_update_submitted_qc>March 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dermatitis</keyword>
  <keyword>Dermatitis, Atopic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
    <mesh_term>Dexchlorpheniramine</mesh_term>
    <mesh_term>Chlorpheniramine</mesh_term>
    <mesh_term>Clemastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

